Adherence to treatment with non-Vitamin K antagonist anticoagulants: Once- vs. twice-daily regimens

Europace

Volumn 17, Issue 8, 2015, Pages 1316-

  Adler, Marcel ^a   Nagler, Michael ^b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; NEW ORAL ANTICOAGULANT AGENT; RIVAROXABAN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CLINICAL PRACTICE; DOSAGE SCHEDULE COMPARISON; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MINIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; TREATMENT OUTCOME; DRUG ADMINISTRATION;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; THROMBOEMBOLISM;

EID: 84939614753     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv107     Document Type: Letter

References (5)

1. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
2. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28:669-80
3. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010;50:1041-52
4. MueckW, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61
5. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53:1-16.